...
首页> 外文期刊>Molecular pharmaceutics >Nanofiber Dressings Topically Delivering Molecularly Engineered Human Cathelicidin Peptides for the Treatment of Biofilms in Chronic Wounds
【24h】

Nanofiber Dressings Topically Delivering Molecularly Engineered Human Cathelicidin Peptides for the Treatment of Biofilms in Chronic Wounds

机译:纳米纤维敷料局部递送分子工程的人类植物疗法肽,用于治疗慢性伤口的生物膜

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Biofilms of multidrug-resistant bacteria in chronic wounds pose a great challenge in wound care. Herein, we report the topical delivery of molecularly engineered antimicrobial peptides using electrospun nanofiber dressings as a carrier for the treatment of biofilms of multidrug-resistant bacteria in diabetic wounds. Molecularly engineered human cathelicidin peptide 17BIPHE2 was successfully encapsulated in the core of pluronic F127/17BIPHE2-PCL core-shell nanofibers. The in vitro release profiles of 17BIPHE2 showed an in initial burst followed by a sustained release over 4 weeks. The peptide nanofiber formulations effectively killed methicillin-resistant Staphylococcus aureus (MRSA) USA300. Similarly, the 17BIPHE2 peptide containing nanofibers could also effectively kill other bacteria including Klebsiella pneumoniae (10(4) to 10(6) CFU) and Acinetobacter baumannii (10(4) to 10(7) CFU) clinical strains in vitro without showing evident cytotoxicity to skin cells and monocytes. Importantly, 17BIPHE2-containing nanofiber dressings without debridement caused five-magnitude decreases of the MRSA USA300 CFU in a biofilm-containing chronic wound model based on type II diabetic mice. In combination with debridement, 17BIPHE2-containing nanofiber dressings could completely eliminate the biofilms, providing one possible solution to chronic wound treatment. Taken together, the biodegradable nanofiber-based wound dressings developed in this study can be utilized to effectively deliver molecularly engineered peptides to treat biofilm-containing chronic wounds.
机译:慢性伤口的多药抗菌的生物膜在伤口护理中提出了巨大的挑战。在此,我们使用Electromet纳米纤维敷料作为用于治疗糖尿病伤口的多药抗菌的生物膜的载体的分子工程抗微生物肽的局部递送。分子工程化的人类疗法蛋白肽17biphe2成功包封在pluronic f127 / 17biphe2-pcl核壳纳米纤维的核心中。 17biphe2的体外释放曲线显示出初始爆发,然后在4周内持续释放。肽纳米纤维制剂有效地杀死了耐甲氧西林金黄色葡萄球菌(MRSA)USA300。类似地,含有纳米纤维的17biphe2肽也可以有效地杀死包括Klebsiella肺炎(10(4)至10(6)个CFU)和在体外的患者(10(4)至10(7)CFU)临床菌株的其他细菌而不显示出明显细胞毒性对皮肤细胞和单核细胞。重要的是,基于II型糖尿病小鼠的含生物膜的慢性伤口模型,含有17biphe2的纳米纤维敷料没有创造的纳米纤维敷料。结合清创,含17biphe2的纳米纤维敷料可以完全消除生物膜,为慢性伤口处理提供一种可能的溶液。在该研究中开发的可生物降解的纳米纤维的伤口敷料可用于有效地递送分子工程肽以治疗含生物膜的慢性伤口。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号